Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ADMA - ADMA Biologics, Inc. So'nggi Yangiliklar | Finranks

Home

ADMA

A

ADMA Biologics, Inc. (ADMA)

NGM – Real vaqt narxi. Valyuta: USD

9.25

+0.96 (11.58%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

9.40

+0.15 (1.62%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, “ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported.

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos.

Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options

Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims

Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines

$ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law

$ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law

ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA

Videolar

No Data

There is no data to display

Press-relizlar

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, “ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported.

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos.

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options

Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims

Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning potential violations of the federal securities laws. On the Q4 2025 earnings call, CEO Adam Grossman stated "ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.